Junshi Biosciences Outlicenses Near-Market Anti-IL-17A Monoclonal Antibody in Strategic Portfolio Realignment

　　【Pharmaceutical Network Corporate News] Recently, Junshi Biosciences announced that on June 30, the company signed a License Agreement with Jiangsu Wanbang Biopharmaceuticals, a wholly-owned subsidiary of Fosun Pharma, to transfer the exclusive rights for the development, registration, manufacturing, and commercialization of its self-developed anti-IL-17A monoclonal antibody, Ruokiqibaimab (JS005), in the Greater China region. The total maximum value of this transaction exceeds RMB 1.34 billion, including an upfront payment of RMB 215 million, milestone payments totaling RMB 1.125 billion, plus double-digit percentage sales royalties.
 

It is understood that ruokiqibai monoclonal antibody is a specific anti-IL-17A monoclonal antibody independently developed by Junshi Biosciences. In December 2025, the New Drug Application (NDA) for ruokiqibai monoclonal antibody for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy was accepted by the National Medical Products Administration (NMPA). Currently, all participants in the Phase II clinical trial of this drug for the treatment of active ankylosing spondylitis (AS) have completed study follow-up.
 

Industry analysts believe that the core reason for Junshi Biosciences licensing the Greater China rights of its IL-17A inhibitor, surucibart, to Fosun Pharma is that the IL-17A therapeutic landscape has become a "red ocean," with intensifying competitive pressure. It is reported that IL-17A stands for Interleukin-17A. Dysregulated secretion of this cytokine can trigger a series of diseases, including psoriasis, ankylosing spondylitis, and rheumatoid arthritis.
 

Currently, multiple IL-17A-targeted drugs from Novartis, Eli Lilly, Hengrui Medicine, Akeso, and 3SBio have been approved in China, with several others in the application stage. For instance, in June 2026, the marketing application for Giant Biogene’s secukinumab injection was accepted. In September 2024, Sundia MediTech’s funakizumab injection was also approved for marketing, indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Although Junshi Biosciences’ JS005 demonstrated industry-leading efficacy in Phase III clinical trials, as a late entrant, it faces significant challenges in breaking through based solely on product data.
 

Furthermore, Junshi Biosciences’ core resources are currently concentrated on its oncology pipeline. The company lacks sufficient capital and manpower to establish an independent commercialization infrastructure for autoimmune diseases, and significant operational pressure is also a major driver behind the divestment. Jiangsu Wanbang Biopharmaceuticals has long been deeply engaged in the autoimmune field, possessing an established national academic promotion team, hospital distribution channels, a patient and physician education system, and experience in securing national reimbursement list inclusion. These capabilities can substantially shorten the ramp-up period for JS005 post-launch, thereby accelerating the realization of its clinical and commercial value.
 

In fact, Junshi Biosciences’ licensing of toripalimab to Jiangsu Wanbang Biopharmaceuticals marks a shift in its business development (BD) strategy from “globalizing core products” to “promoting external collaborations for non-core pipelines and accelerating commercial monetization.” This “R&D + commercialization” division-of-labor model helps Junshi secure cash flow upfront and focus on the R&D of its core pipeline. For Jiangsu Wanbang, it enables rapid supplementation with high-quality products and strengthens its portfolio in the autoimmune disease sector. Furthermore, for patients, a mature commercialization system is expected to facilitate faster and broader clinical access to new therapies.
 

Overall, the collaboration between Junshi Biosciences and Fosun may be just the beginning. In the future, more combinations of "R&D-focused pharmaceutical companies + leading commercialization partners" are likely to emerge within the industry, jointly accelerating the high-quality development of China's innovative drug sector.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.